|
Exosomal Drug Delivery
|
5R44CA221487-02
|
$1,000,000
|
SPENCER, WENDY
|
3P BIOTECHNOLOGIES, INC.
|
|
Compact Navigation System for CT-guided Needle Interventions
|
1UT1CA224886-01A1
|
$149,927
|
TSE, TSZ HO
|
3T TECHNOLOGIES, LLC
|
|
Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies
|
5R44CA162629-03
|
$833,374
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia
|
5R44CA221539-02
|
$660,235
|
RODGERS, BUEL
|
AAVOGEN, INC.
|
|
Personalized precision dosing of biologic therapies in oncology
|
5R44CA217336-02
|
$720,363
|
MESSMER, BRADLEY
|
ABREOS BIOSCIENCES, INC.
|
|
Novel targeted therapy for pancreatic cancer
|
1R43CA221555-01A1
|
$299,979
|
HERRERA, VICTORIA
|
ABTELUM BIOMEDICAL, INC.
|
|
Innovation Corp Program and Commercialization Planning for Endoscopic Flexible Pancreatic Tumor Ablation System with Reduced Force Effector and Specialized Ablation Zone
|
3R43CA225169-01S1
|
$49,999
|
SNOOK, KEVIN
|
ACTUATED MEDICAL, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
2R44CA200161-02A1
|
$1,000,000
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
3R41CA200161-01A1S3
|
$3,000
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
Implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial
|
4R44CA224460-02
|
$1,111,364
|
DAUNCH, WILLIAM
|
ADVANCED CHEMOTHERAPY TECHNOLOGIES, INC.
|
|
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation
|
4R44CA203336-02
|
$659,516
|
AGUILAR-CORDOVA, ESTUARDO
|
ADVANTAGENE, INC
|
|
A Novel Immunotherapy Targeting Cancer Stem Cells for the Treatment of Triple-Negative Breast Cancer
|
1R44CA224835-01A1
|
$298,864
|
PERICLE, FEDERICA
|
AGILVAX, INC.
|
|
Distance Education to Engage Alaskan Community Health Aides in Cancer Control
|
5R25CA186882-05
|
$135,579
|
CUEVA, MELANY
|
ALASKA NATIVE TRIBAL HEALTH CONSORTIUM
|
|
Novel Strategies for Precision T-cell Therapies
|
3R01CA198095-03S1
|
$107,431
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Novel Strategies for Precision T-cell Therapies
|
5R01CA198095-03
|
$520,564
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Core Support for Cancer Center
|
3P30CA013330-45S1
|
$3,646,138
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Inhibition of Senescence to Increase Cancer Cell Death: A New Paradigm
|
5R01CA077263-19
|
$417,500
|
MCDAID, HAYLEY
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
RCT of An Internet Cessation Program Plus Online Social Network for HIV + Smokers
|
5R01CA192954-05
|
$626,669
|
SHUTER, JONATHAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Identification and targeting of pathways separating healthy stem cell aging from malignant transformation
|
1R01CA230756-01
|
$382,013
|
WILL, BRITTA
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
11th AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved
|
1R13CA236113-01
|
$74,000
|
FOTI, MARGARET
|
AMERICAN ASSOCIATION FOR CANCER RESEARCH
|
|
Colon cancer risk-stratification via optical analysis of rectal ultrastructure
|
3R44CA199667-02S1
|
$2,000
|
WALI, RAMESH
|
AMERICAN BIOOPTICS, LLC
|
|
Colon cancer risk-stratification via optical analysis of rectal ultrastructure
|
3R44CA199667-02S2
|
$126,060
|
WALI, RAMESH
|
AMERICAN BIOOPTICS, LLC
|
|
Molecular, cancer-specific, intraoperative imaging of breast surgical margin assessment
|
1R41CA221595-01A1
|
$300,000
|
SHIH, WEI-HENG
|
AQD LIFE SCIENCES, LLC
|
|
E6 Oncoprotein Based Rapid Test for Anal Neoplasia
|
5R43CA153808-02
|
$338,612
|
SCHWEIZER, JOHANNES
|
ARBOR VITA CORPORATION
|
|
Developing a mobile application for circadian wellness in cancer patients
|
1R43CA236557-01A1
|
$221,237
|
WALCH, OLIVIA
|
ARCASCOPE, LLC
|
|
WalkIT: Neighborhood walkability and moderation of adaptive walking interventions
|
5R01CA198915-04
|
$568,727
|
ADAMS, MARC
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Couple Communication in Cancer: A Multi-Method Examination
|
3R01CA201179-03S1
|
$227,376
|
LANGER, SHELBY
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Couple Communication in Cancer: A Multi-Method Examination
|
5R01CA201179-03
|
$655,095
|
LANGER, SHELBY
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Effects of Meditative Movement (Qigong/Tai Chi Easy) on Fatigued Breast Cancer Survivors
|
3R01CA182901-04S1
|
$39,254
|
LARKEY, LINDA
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Effects of Meditative Movement (Qigong/Tai Chi Easy) on Fatigued Breast Cancer Survivors
|
5R01CA182901-04
|
$612,939
|
LARKEY, LINDA
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Arizona Cancer and Evolution Center (ACE)
|
1U54CA217376-01A1
|
$1,906,167
|
MALEY, CARLO
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Modeling Neoplastic Progression in Barretts Esophagus
|
5R01CA140657-10
|
$350,771
|
MALEY, CARLO
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Role of IRF8 in Tumor Rejection and Suppression
|
5R01CA133085-09
|
$307,800
|
LIU, KEBIN
|
AUGUSTA UNIVERSITY
|
|
Role of NF-kB in Fas-mediated Apoptosis and Tumor Suppression
|
5R01CA182518-05
|
$315,400
|
LIU, KEBIN
|
AUGUSTA UNIVERSITY
|
|
Rapid Non-Viral Platform for Generation of Genetically Modified T Cells for Therapy
|
1R44CA233143-01
|
$218,588
|
LAMPI HERMANSON, DAVID
|
B-MOGEN BIOTECHNOLOGIES, INC.
|
|
Integrative Oncology: From Research to Practical Applications
|
1R13CA236121-01
|
$5,000
|
RAO, SANTOSH
|
BANNER HEALTH
|
|
Improving pathologic nodal staging of resected lung cancer
|
2R01CA172253-06
|
$499,347
|
OSAROGIAGBON, RAYMOND
|
BAPTIST MEMORIAL HOSPITAL - TIPTON
|
|
Research Supplements to Promote Sharing Data in Cancer Epidemiology Studies
|
3U19CA203654-02S1
|
$147,830
|
AMOS, CHRISTOPHER
|
BAYLOR COLLEGE OF MEDICINE
|
|
A Psychosocial Intervention for the Caregivers of Advanced Lung Cancer Patients
|
5R01CA187143-05
|
$456,456
|
BADR, HODA
|
BAYLOR COLLEGE OF MEDICINE
|
|
Integrative Molecular Epidemiology of Neurocognitive Outcomes in Acute Lymphoblastic Leukemia
|
1K07CA218362-01A1
|
$166,043
|
BROWN, AUSTIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Crosstalk between the ER Stress Response and Mitochondrial Fatty Acid Oxidation in MYC-driven Breast Cancer
|
1R37CA228304-01
|
$362,569
|
CHEN, XI
|
BAYLOR COLLEGE OF MEDICINE
|
|
The Effectiveness of Screening HIV-Infected Women for Anal Cancer Precursors
|
1R01CA163103-01
|
$637,119
|
Chiao, Elizabeth
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQ9) Directed and unbiased studies of synaptic injuries as sequelae of radiotherapy: mapping, sex-dependence, and reversal
|
5R01CA219667-02
|
$523,048
|
DUMAN, JOSEPH
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQ5) Exploring the Biological Distinctions between HIV-related and Endemic Pediatric Kaposi Sarcoma in a Kaposi Sarcoma-Associated Herpesvirus-Endemic Region of Africa
|
5R21CA217137-02
|
$196,947
|
EL-MALLAWANY, NADER
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQ6)Nuclear receptor mechanisms in circadian disruption induced hepatocarcinogenesis
|
1R01CA230848-01
|
$442,560
|
FU, LONING
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQB-1) Telomere maintenance defects and thyroid second cancer in childhood cancer survivors
|
5R01CA194473-04
|
$119,807
|
GRAMATGES, MARIA
|
BAYLOR COLLEGE OF MEDICINE
|
|
SPORE in Lymphoma
|
5P50CA126752-12
|
$2,297,796
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Cognitive Change after Proton RT vs. Photon or Surgery for Pediatric Brain Tumor
|
5R01CA187202-05
|
$577,030
|
KAHALLEY, LISA
|
BAYLOR COLLEGE OF MEDICINE
|
|
Identifying and targeting oncogenic Myc enhancer control in pediatric tumors
|
3R01CA215452-02S1
|
$7,156
|
LIN, CHARLES
|
BAYLOR COLLEGE OF MEDICINE
|
|
Identifying and Targeting Onocgenic MYC Enhancer Control in Pediatric Tumors
|
3R01CA215452-02S2
|
$45,800
|
LIN, CHARLES
|
BAYLOR COLLEGE OF MEDICINE
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|